Ligand Pharmaceuticals Incorporated LGND
Set alert
At close · Nov 2
After hours · Nov 2, 4:32 PM ET
- YTD
- +62.38%
- 1 year
- +60.48%
- Open
- 323.28
- Prev close
- 322.75
- Mkt cap
- 6.14B
- Vol
- 265.43K
- Avg vol
- 240.44K
- EPS
- 9.49
- P/E
- 32.35
- Div yield
- 0.00%
More statistics
- Low
- 306.17
- High
- 324.95
- Forward P/E
- 25.68
- Beta
- 1.03
- Short ratio
- 9.25
- Inst. own
- 116.12%
- Dividend
- 0.00
- Ex-div date
- Jul 1, 2010
- Earnings
- Feb 25, 2027
- 50-d avg
- 296.39
- 200-d avg
- 252.66
- 1y target
- 350.92
5D chart
Events in this range
- Oct 29, 2026Earnings: 2.67; estimate 2.33; surprise 14.59%
- Oct 30, 2026Rating: RBC Capital · Outperform → Outperform
Signals (146)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:50 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 3:40 PM | 11 hours ago |
| MACD: Sell Signal | Nov 2, 3:40 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 11 hours ago |
| RSI: Overbought | Nov 2, 2:55 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 2:35 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 12 hours ago |
| RSI: Oversold | Nov 2, 2:00 PM | 12 hours ago |
| RSI: Oversold | Nov 2, 1:40 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 1:15 PM | 13 hours ago |
| SMA: Bullish | Nov 2, 1:05 PM | 13 hours ago |
| MACD: Buy Signal | Nov 2, 12:55 PM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 12:50 PM | 14 hours ago |
| RSI: Oversold | Nov 2, 12:45 PM | 14 hours ago |
| MACD: Buy Signal | Nov 2, 12:25 PM | 14 hours ago |
| MACD: Sell Signal | Nov 2, 10:50 AM | 16 hours ago |
| SMA: Bearish | Nov 2, 10:40 AM | 16 hours ago |
| SMA: Bearish | Nov 2, 10:40 AM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 10:25 AM | 16 hours ago |
Newest 20 of 146.
News
-
3 days ago benzinga.com
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.
4 days ago seekingalpha.com
Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Melanie Herman - Executive Director of Investor Relations and Financial Planning &…
4 days ago marketbeat.com
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
Ligand Pharmaceuticals NASDAQ: LGND reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired…
4 days ago benzinga.com
Ligand Pharmaceuticals Q3 2026 Earnings Call Transcript
Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
-
4 days ago benzinga.com
Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est
Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 analyst estimate. Lowers FY2026 sales outlook from $270.000 million-$310.000 million to…
-
4 days ago benzinga.com
Ligand Pharmaceuticals Q3 Adj. EPS $2.67 Beats $2.38 Estimate, Sales $78.700M Beat $77.232M Estimate
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $2.67 per share which beat the analyst consensus estimate of $2.38 by 12.18 percent. This is a 13.59 percent decrease over earnings…
4 days ago globenewswire.com
Ligand Reports Third Quarter 2026 Financial Results
Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance…
6 days ago globenewswire.com
Ligand to Participate in November Investor Conferences
JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor…
1 week ago benzinga.com
Here's How Much $1000 Invested In Ligand Pharmaceuticals 20 Years Ago Would Be Worth Today
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 20 years by 12.04% on an annualized basis producing an average annual return of 20.96%. Currently, Ligand…
1 week ago globenewswire.com
Ligand to Host Investor Day on December 8, 2026
JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from…
2 weeks ago globenewswire.com
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29,…
2 weeks ago benzinga.com
Here's How Much $1000 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth Today
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 13.64% on an annualized basis producing an average annual return of 26.84%. Currently, Ligand…
3 weeks ago benzinga.com
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call
On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
-
1 month ago benzinga.com
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.
1 month ago globenewswire.com
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a…
-
1 month ago benzinga.com
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.
-
1 month ago benzinga.com
Sydnexis Signs $23M Agreement With Ligand Pharmaceuticals To Sell Its Royalty Rights Associated With Net Sales Of Ryjunea In EMEA
Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand…
1 month ago businesswire.com
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced…
1 month ago prnewswire.com
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by…
1 month ago globenewswire.com
Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million
Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to…
-
1 month ago benzinga.com
Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on an annualized basis producing an average annual return of 27.11%. Currently, Ligand Pharmaceuticals…
1 month ago seekingalpha.com
Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech
Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND's future prospects, emphasizing its key royalty producing assets. LGND is…
1 month ago defenseworld.net
Reviewing Omeros (NASDAQ:OMER) & Ligand Pharmaceuticals (NASDAQ:LGND)
Omeros (NASDAQ: OMER - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
2 months ago benzinga.com
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals…
2 months ago marketbeat.com
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage…
2 months ago globenewswire.com
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor…
-
2 months ago benzinga.com
$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 16.18%. Currently, Ligand Pharmaceuticals…
2 months ago defenseworld.net
Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND
Handelsbanken Fonder AB boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 22.5% in the undefined quarter, according to the company in its most recent 13F filing with the…
-
2 months ago benzinga.com
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330
Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $340 to $345.
2 months ago marketbeat.com
Ligand Pharmaceuticals Q2 Earnings Call Highlights
Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty…
2 months ago seekingalpha.com
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $289 to $358.
-
2 months ago benzinga.com
Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est
Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to…
-
2 months ago benzinga.com
$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand…
3 months ago defenseworld.net
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 27.3% in the undefined quarter, according to the company in its most recent 13F…
-
3 months ago benzinga.com
Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326
Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $285 to $326.
3 months ago defenseworld.net
Ashford Capital Management Inc. Has $41.44 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND
Ashford Capital Management Inc. reduced its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% in the first quarter, according to its most recent filing with the…
3 months ago globenewswire.com
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6,…
-
3 months ago benzinga.com
Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target
Citigroup analyst Yigal Nochomovitz reinstates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and announces $387 price target.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $340
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $262 to $340.
3 months ago benzinga.com
Why Is Agenus Stock Falling on Tuesday?
Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the latest clinical data and analyst updates.
3 months ago benzinga.com
Why Is Agenus Stock Gaining Monday?
Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.
-
3 months ago benzinga.com
B of A Securities Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $388
B of A Securities analyst Jason Zemansky maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $266 to $388.
-
3 months ago benzinga.com
Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $332
Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $255 to $332.
-
4 months ago benzinga.com
Ligand Plans $550M Convertible Notes Offering, To Use Notes Sale for Share Buybacks and Corporate Needs
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a
4 months ago benzinga.com
7 Health Care Stocks With Whale Alerts In Today's Session
7 Health Care Stocks With Whale Alerts In Today's Session
-
5 months ago benzinga.com
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $262
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $252 to $262.
-
5 months ago benzinga.com
Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.50-$9.50 vs $9.13 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $281.535M Est
Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.50-$9.50 to $8.50-$9.50 vs $9.13 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to…